Email this article INTEGRATION OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER CHEMOTHERAPY REGIMENS IN 2 CLINICAL CENTERS IN MOSCOW AND SAINT PETERSBURG
- Authors: Dobrova N.V.1, Semenov N.N.1, Manikhas G.M.2, Antimonik N.Y.2, Vakhabova Y.V.1, Gutorov S.L.1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
- Municipal Clinical Oncological Dispensary, Saint Petersburg
- Issue: Vol 2, No 4 (2013)
- Pages: 50-56
- Section: ORIGINAL REPORTS
- Published: 01.03.2015
- URL: https://onco-surgery.info/jour/article/view/99
- DOI: https://doi.org/10.17650/2220-3478-2013-0-4-50-56
- ID: 99
Cite item
Full Text
Abstract
The aim of this study was to estimate efficacy of first line chemotherapy with bevacizumab in metastatic colorectal cancer patients and investigate the impact of different prognostic factors on treatment outcome.
Methods.During 2004–2008 48 colorectal cancer patients were included (29 in Russian N.N. Blokhin Cancer Research Center, 19 in St. Petersburg), who had unresectable distant metastases. Primary tumor was resected in 93.8 % patients. 52.1 % had rectal cancer. 87.5 % had liver metastases, 43.8 % had more than 1 organ affected. 66.7 % received chemotherapy with bevacizumab 5 mg/kg biweekly, 33.3 % received bevacizumab 7,5 mg/kg every 3 weeks. 62.5 % patients had oxaliplatin-based regimens, 35.4 % – only fluorpyrimidines, 2.1 % – chemotherapy with irinotecan.
Results.Median time of bevacizumab use was 7.8 months. 60.3 % had objective response, 87.4 % had stable diseases during more than 6 months. Median progression-free survival (PFS) was 11.5 months. Median overall survival (OS) was 24.1 months.
Conclusions.Survival and efficacy results are comparable to international experience. Combination of fluorpyrimidines with bevacizumab had comparable efficacy to combined chemotherapy regimens with no impact on quality of life. Integration of bevacizumab in combined treatment regimens reduced the impact of negative prognostic factors on PFS and OS.
Keywords
About the authors
N. V. Dobrova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Author for correspondence.
Email: dobrova2008@rambler.ru
Russian Federation
N. N. Semenov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: dobrova2008@rambler.ru
Russian Federation
G. M. Manikhas
Municipal Clinical Oncological Dispensary, Saint Petersburg
Email: dobrova2008@rambler.ru
Russian Federation
N. Yu. Antimonik
Municipal Clinical Oncological Dispensary, Saint Petersburg
Email: dobrova2008@rambler.ru
Russian Federation
Yu. V. Vakhabova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: dobrova2008@rambler.ru
Russian Federation
S. L. Gutorov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: dobrova2008@rambler.ru
Russian Federation
References
Supplementary files
